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Abstract: Acne is a disease of the pilosebaceous unit with involving abnormalities in sebum 
production, microbial ﬂ  ora changes, abnormal keratinization, and inﬂ  ammation. There are 
several therapeutic options like topical and systemic retinoids, antibiotics, and systemic hor-
monal drugs. The topical retinoids a play very important role in the treatment of acne vulgaris. 
However, their use is limited due to skin irritation. A new generation product, adapalene is a 
good choice in the treatment of acne vulgaris with less side effects and high efﬁ  cacy conﬁ  rmed 
by numerous clinical studies.
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Introduction
Acne vulgaris is a chronic, inﬂ  ammatory disease of the pilosebaceous unit, that affects 
seborrhoeic areas like face, back, and chest and characterized by comedones, papules, 
pustules, nodules, cysts, and scars. Almost every individual has some degree of acne 
during puberty with spontaneous resolution occurring in early adult life. Occasionally, 
the disease persists into the fourth decade or even remains a lifelong problem. Because 
of the involvement of the face with considerable cosmetic problems, acne is a major 
psychosocial problem for many teenagers and young adults (Cunliffe and Simpson 
1998; Strauss and Thiboutot 1999; Braun-Falco et al 2001).
The pathogenesis of acne
In the pathogenesis of acne, the most important site is pilosebaceous unit which consists 
of a hair follicle and several sebaceous glands. These units are found everywhere on 
the body except the palms and soles. Pilosebaceous density is greatest on the face, 
upper neck, and chest, in roughly nine times the concentration found elsewhere on 
the body (Leyden 1995; Habif and Habie 1996).
There are four main interacting factors in the pathogenesis of acne vulgaris:
a)  Increased sebum production,
b) Microbial  ﬂ  ora changes,
c) Abnormal  keratinization,
d) Inﬂ  ammation (Strasburger 1997; Cunliffe and Simpson 1998; Braun-Falco et al 
2001; Korkut and Piskin 2005).
To be able to treat acne, these factors should be targeted. The aim is to reduce 
or eliminate the primary clinical lesion, microcomedone, which is the precursor of 
almost all other acne lesions (Cunliffe et al 2003). There are a lot of topical or systemic 
agents for this purpose.
Treatment
The treatment of acne vulgaris is not curative. The purpose is to reduce discomfort 
due to inﬂ  amed lesions, to improve the appearance, and to prevent scars. Acne Therapeutics and Clinical Risk Management 2007:3(4) 622
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management is a long-term treatment and requires patience. 
The patient should be informed on the issue (Cunliffe and 
Simpson 1998; Oberomok and Shalita 2002).
Topical preparations constitute the sole treatment in 
many patients with acne vulgaris and are a part of therapeutic 
regimen in almost all patients. Topical treatment is enough 
for comedonal acne. In case of more severe acne, topical 
treatment can be combined with systemic treatment (Cunliffe 
and Simpson 1998).
Topical treatment of acne vulgaris has changed over the 
years. Agents containing sulphur or resorcinol were used in 
especially ﬁ  rst part of 20th century. Salicylic acid which is a 
keratolytic agent was popular in some time. Nowadays, the 
most popular topical agents were retinoids, benzoyl peroxide, 
azelaic acid, and topical antibiotics (Bergfeld 1998).
Topical retinoids
Topical retinoids, derivatives of vitamin A have been used 
to treat acne for almost three decades. They are the most 
effective comedolytic agents for the treatment of acne 
vulgaris by normalizing or even increasing the desquamation 
process, thereby decreasing the formation and the number of 
microcomedones. They also promote the clearing of preexist-
ing comedones (Bergfel 1998) and decrease in papulopustular 
lesions (Ellis et al 1998; Thiboutot et al 2001; Bershad et al 
2002). In addition, they have a marked anti-inﬂ  ammatory 
effect by inhibiting the activity of leukocytes, the release 
of pro-inﬂ  ammatory cytokines and other mediators, and the 
expression of transcription factors and toll-like receptors 
involved in immunomodulation. They also help penetra-
tion of other active agents. Thus, they should be utilized in 
nearly every patient with acne and are the preferred agents 
in maintenance therapy (James et al 2000).
Until recently, tretinoin, which is the active form of 
a metabolic product of vitamin A, was the only available 
topical retinoid (Leyden 1998). However, its use has been 
limited by local irritation after initiation of therapy. This side 
effect is a minimal problem with the third generation topical 
retinoids, such as adapalane. Tretinoin is available in a new 
delivery system (Retin-A Micro) to decrease the irritative 
effects. The purpose in this delivery system is to provide the 
drug directly to the follicle by entrapping it in microspheres 
(Skov et al 1997).
Adapalene
Adapalene is a synthetic naphthoic acid derivative with 
retinoid activity. The chemical name of adapalene is 
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid. 
Adapalene is a white to off-white powder which is soluble in 
tetrahydrofuran, sparingly soluble in ethanol, and practically 
insoluble in water. The molecular formula is C28H28O3 and 
molecular weight is 412.52. Adapalene is represented by the 
structural formula represented on Figure 1.
Some of its biologic activities are the same with tretinoin, 
however it is chemically more stable and lipophilic. By this 
way, it can reach higher concentrations in pilosebaceous unit. 
In addition, it has higher afﬁ  nity towards retinoic acid recep-
tor (RAR) β and γ unlike tretinoin. It is important because 
epithelial cells have mainly RAR γ. Then, RAR-adapalene 
complex binds retinoid X receptor (RXR) and this regulates 
gene transcription by binding speciﬁ  c DNA sites (Leyden 
1998; Czernielewski et al 2001). Adapalene modulates 
cellular keratinization and inﬂ  ammatory process. This anti-
inﬂ  ammatory effect is due to inhibition of the lipooxygenase 
activity and also to oxidative metabolism of arachidonic acid. 
These mechanisms may be the reason for decreased risk of 
irritation with adapalene. Adapalene has a very low percu-
taneous absorption once the drug has penetrated the stratum 
corneum, so that it becomes entrapped in the epidermis and 
hair follicle, which are targeted areas (Millikan 2000).
Absorption of adapalene through human skin is low. 
Only trace amounts (0.25 ng/ml) of parent substance have 
been found in the plasma of acne patients following chronic 
topical application of adapalene in controlled trials. Excretion 
appears to be primarily by the biliary route. Erythema, peel-
ing, dryness and burning are the most frequent encountered 
side effects.
Clinical studies
Over the past five years, numerous clinical trials have 
been conducted on comparing the efficacy and tolerability 
of adapalene and tretinoin in the treatment of acne vul-
garis. A meta-analysis of five large studies with more than 
900 patients over 12 weeks demonstrated that adapalene 
0.1% gel is as effective as tretinoin 0.025% gel (Cunliffe 
Figure 1 Structural formula of adapalene.Therapeutics and Clinical Risk Management 2007:3(4) 623
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et al 1998). After 12 weeks, both agents were equally ef-
fective but adapalene had a faster onset of action and less 
irritation. However, the comparison of adapalene 0.1% 
gel and tretinoin 0.1% microsphere gel in a double-blind 
study demonstrated more rapid comedone reduction with 
the tretinoin gel than with adapalene, but again, there was 
less irritation in patients using adapalene (Nyirady et al 
2001). Grosshans et al (1998) compared 0.1% adapalene 
and 0.025% tretinoin on 105 patients for 3 months and 
Ellis et al (1998) compared 0.1% adapalene and 0.025% 
tretinoin on 297 patients for 3 months. In both of these 
studies, there was no difference between these drugs in 
terms of efficacy. In another study, Cunliffe et al (1997) 
compared 0.1% adapalene and 0.025% tretinoin on 323 
patients for 3 months. They found that adapalene caused 
more decrease in total and noninflammatory lesions than 
tretinoin. However, there was no significant difference in 
terms of inflammatory lesions. Korkut and Piskin (2005) 
demonstrated that adapalane is more effective in nonin-
flammatory lesions than inflammatory lesions.
Adapalene 0.1% gel has been studied in 80 patients 
against isotretinoin 0.05% gel, which is the cis-isomer of 
retinoic acid, to compare their effectiveness and tolerance 
by Ioannides et al (2002). Both lesion counts and global 
assessment showed a better degree of efﬁ  cacy with adapalene 
than isotretinoin, although the difference between two drugs 
was not signiﬁ  cant. Although isotretinoin is less irritating 
than tretinoin, adapalene is signiﬁ  cantly less irritating than 
isotretinoin.
In the study comparing tazarotene applied every other day 
and adapalene applied daily by Guenther (2003), both drugs 
had comparable efﬁ  cacy and tolerability. Dosik et al (2005) 
performed a study to compare the ability of epidermis to 
tolerate adapalene 0.1% cream and gel and tazarotene 0.05% 
and 0.1% creams on 26 subjects for a period of three weeks. 
The mean 21-day cumulative irritancy indices for adapalene 
0.1% cream and gel were signiﬁ  cantly lower than those for 
tazarotene 0.05% and 0.1% creams and not notably higher 
than that of negative control.
A multicenter, randomized, double-blind study by 
Thiboutot et al (2006a) on 653 patients demonstrated that 
adapalene 0.3% gel was signiﬁ  cantly superior to adapalene 
0.1% gel and well-tolerated. In another study, the efﬁ  cacy 
and safety of adapalene 0.3% gel were compared with ada-
palene 0.1% gel and vehicle on 214 subjects for 12 weeks. 
The results of this study demonstrated that adapalene gel 
0.3% was superior to adapalene 0.1% gel and vehicle in 
moderate to moderately severe acne while retaining a similar 
study and tolerability proﬁ  le to adapalene 0.1% gel (Pariser 
et al 2005).
Benzoyl peroxide and adapalene are among the most 
effective topical agents used in the treatment of acne vulgaris. 
Despite the fact that there are a lot of studies with benzoyl 
peroxide and adapalene alone, there are only a few studies 
comparing these two drugs. do Nascimento et al (2003) 
compared the efﬁ  cacy and safety of benzoyl peroxide 4% gel 
used twice daily with adapalene 0.1% gel used once daily on 
178 patients for 11 weeks. They found benzoyl peroxide more 
effective than adapalane on noninﬂ  ammatory and inﬂ  amma-
tory lesions at weeks 2 and 5, and they found both drugs safe. 
Korkut and Piskin (2005) have compared the efﬁ  cacy and 
safety of 5% benzoyl peroxide, 0.1% adapalene, and their 
combination. The study revealed that all three therapeutic 
protocols were effective in treating noninﬂ  ammatory and 
inﬂ  ammatory lesions and that there were no signiﬁ  cant differ-
ence between the groups in terms of efﬁ  cacy or side effects. 
Adapalene and benzoyl peroxide are effective and well tol-
erated agents for acne vulgaris; combination therapy has no 
superiority over adapalene or benzoyl peroxide alone. There 
are a few studies that compare the side effects of benzoyl 
peroxide and adapalene. Brand et al (2003) demonstrated 
that 0.1% adapalene and 5% benzoyl peroxide combination 
was safe and well-tolerated.
Thiboutot et al (2005) compared the efﬁ  cacy and safety 
of the combination of adapalene 0.1% gel and doxycycline 
with doxycycline alone for severe acne vulgaris. This study 
demonstrated that the combination of adapalene and an oral 
antibiotic provide a superior and faster beneﬁ  t than antibiotic 
alone and should be considered in the initiation treatment.
Adapalene is also useful in maintenance therapy. 
Thiboutot et al (2006b) performed a study on 253 subjects 
to assess the maintenance effect of adapalene 0.1% gel and 
gel vehicle in subjects successfully treated in a previous 
12 week study of adapalene-doxycycline combination. The 
study demonstrated a clinical beneﬁ  t of continued treatment 
with adapalene 0.1% gel as a maintenance therapy. In another 
study by Zhang et al (2004), a total of 300 acne subjects 
entered the multicentre, randomized, investigator-blinded 
study comparing the efﬁ  cacy and safety of adapalene 0.1% 
gel plus clindamycin 1% solution versus clindamycin 
1% solution alone. In the second part of the study (weeks 
12–24) completed by 241 subjects, the efﬁ  cacy and safety 
of adapalene 0.1% gel alone as a maintenance therapy 
were investigated. This study conﬁ  rmed the importance of 
a maintenance therapy after a successful initial treatment 
and underlined the beneﬁ  t of a combination therapy with a Therapeutics and Clinical Risk Management 2007:3(4) 624
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topical retinoid such as adapalane and a topical antibiotic in 
the treatment of inﬂ  ammatory acne.
Adapalene treatment has a theoretical risk for retinoid 
embryopathy. However, manufacturer reports that only 
trace amounts of adapalene are absorbed into the skin. In 
the manufacturer’s studies on pregnant animals using doses 
120–150 times the human topical dose did not show an 
increased risk of adverse outcome or malformations. There 
have not been performed human studies to date, so the risk 
is undetermined for adapalene usage in pregnancy. However, 
because only trace amounts of the drug absorb into skin, it 
seems unlikely the drug induces malformations.
In summary, numerous clinical studies demonstrating that 
adapalene treatment is a good choice for topical treatment of 
acne vulgaris with less side effects and high efﬁ  cacy.
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